ALL announcements
Expansion of distribution partnership in Europe
Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership
Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
See More 
Actylis Acquires Pharm-Rx
Strengthening Our Commitment to Innovation and Customer Success in VMS and Pharma
We are delighted to announce the strategic acquisition of Pharm-Rx. This acquisition significantly enhances our ability to deliver exceptional value to our customers, increase our range of solutions for clients, and strengthen our strategic supplier partnerships to enhance our innovative portfolio and service offerings. Pharm-Rx’s strong team and industry expertise broadens our capabilities to help accelerate growth with nutrition and over-the-counter (OTC) pharmaceutical customers.
See More
Actylis Achieves Gold top 5% EcoVadis Rating
Actylis Achieves Gold EcoVadis Rating, Demonstrating Commitment to Sustainability Excellence
Actylis is proud to announce its attainment of a Gold rating from EcoVadis, solidifying its position in the top 5 percentile among industry peers. This remarkable achievement underscores Actylis' unwavering commitment to sustainable practices and its dedication to fostering a more responsible and eco-conscious future.
See More
Actylis, NCS South Africa, and Agni Chemicals Announce Tripartite Partnership
Actylis, NCS South Africa, and Agni Chemicals Announce Tripartite Partnership
Actylis has joined forces with NCS, a prominent South African polymer manufacturer with over 100 years in the paint and coatings industry, and Agni Chemicals, a creative entrepreneurial chemical supply chain company, to provide coating resins in North America from a new and reliable source outside of the APAC region.
See More
Actylis Expands WFI Manufacturing Capabilities in Canada
Actylis launched Water for Injection (WFI) and additional ISO Class 7 manufacturing space in Canada
Actylis today announced the launch of Water for Injection (WFI) and additional ISO Class 7 manufacturing space at its Baie d’Urfé site in Montreal, Canada. Used for the preparation of media, buffers, and other aqueous solutions, Actylis’ WFI meets monographs for pharmacopoeias worldwide, and can be provided in both custom and standard packaging configurations.
See More
Actylis opens innovative API manufacturing cGMP facility in Oregon, USA
Actylis opens a 30,000ft2 cGMP facility in Eugene, OR, USA to bolster our innovative API manufacturing capabilities.
The new facility focuses on the manufacture of innovative APIs and excipients at both clinical trial and full commercial scale. Our new state-of-the-art facility has 7 manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3. We have a number of different reactors to allow flexibility for a variety of chemistries.